Financial Performance - The company reported a significant increase in revenue, achieving a total of RMB 1.5 billion, representing a growth of 15% compared to the previous year[15]. - The net profit for the year was RMB 300 million, reflecting a 10% increase year-over-year[15]. - Operating income for 2021 reached RMB 6,560,077,586.40, representing a 9.23% increase compared to 2020[19]. - Net profits attributable to shareholders of the listed company increased by 7.29% to RMB 348,548,495.99 in 2021[19]. - The net profit attributable to the company for 2021 was RMB 57,212,663.89, an increase from RMB 34,069,550.32 in 2020, representing a growth of about 68%[27]. - The company has set a performance guidance for the next year, aiming for a revenue target of RMB 1.8 billion, which would represent a 20% increase[15]. - The gross profit margin improved to 40%, up from 35% in the previous year, indicating better cost management and pricing strategies[79]. Customer Growth - User data showed an increase in active customers, reaching 2 million, which is a 20% growth from the previous year[15]. - User data indicates a growing customer base, with an increase of 25% in active users compared to the previous year, reaching 500,000 active users[79]. Market Expansion - The company plans to expand its market presence in Southeast Asia, targeting a 25% increase in market share by 2023[15]. - The company plans to expand its market presence in Southeast Asia, with an investment of 50 million RMB allocated for marketing and distribution channels[79]. Product Development - New product development includes the launch of three innovative pharmaceutical products, expected to contribute an additional RMB 200 million in revenue[15]. - New product development is underway, with three new pharmaceutical products expected to launch in Q3 2022, targeting a market share increase of 10%[79]. Strategic Initiatives - A strategic acquisition of a smaller pharmaceutical firm was completed, enhancing the company's product portfolio and expected to generate an additional RMB 150 million in annual revenue[15]. - A strategic acquisition of a local competitor is in progress, which is expected to enhance the company's production capacity by 30%[79]. Research and Development - The company has allocated RMB 100 million for research and development in new technologies for the upcoming fiscal year[15]. - The company is investing in advanced technology for drug development, with a budget of 100 million RMB dedicated to R&D over the next two years[79]. Sustainability and Corporate Responsibility - The board emphasized the importance of sustainability and corporate social responsibility initiatives, with a budget of RMB 50 million allocated for environmental projects[15]. - The company has initiated a new sustainability strategy aimed at reducing carbon emissions by 25% by 2025[79]. Financial Position - The company reported a strong cash flow position with RMB 500 million in cash reserves, providing a solid foundation for future investments[15]. - Total assets as of December 31, 2021, were RMB 7,332,033,657.98, reflecting a 3.37% increase from the previous year[19]. - Total liabilities decreased by 0.56% to RMB 3,680,888,823.85 as of December 31, 2021[19]. Shareholder Information - The total number of shares as of December 31, 2021, was 627,367,447, an increase from 621,859,447 shares in 2020[36]. - The company plans to propose a final dividend of RMB 0.15 per share based on a total share count of 669,627,235, subject to shareholder approval[62]. - The proposed A share issuance is currently in progress, and the Company will not discuss the profit distribution plan for 2021 until after the issuance is completed[61]. Management and Governance - The term of the current Directors, Supervisors, and Senior Officers will end on December 22, 2023[101]. - The company operates independently from its controlling shareholder in terms of business, assets, management, and finance[156]. - The Company has established clear responsibilities among its governance structures, including the board of directors and supervisory committee[162]. Internal Controls and Auditing - The Audit Committee confirmed that the financial statements for 2021 were prepared in accordance with the Company's accounting policies and were accurate without any material misrepresentations[143]. - An independent audit on the effectiveness of the Company's internal control was conducted by ShineWing, ensuring transparency and accountability[174]. - The internal control audit report confirmed that the Company maintained effective internal control over financial reporting as of December 31, 2021, in compliance with relevant regulations[183][186].

山东新华制药股份有限公司 2022 年第一季度报告全文 重要内容提示: 山东新华制药股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗 漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 1 证券代码：000756 证券简称：新华制药 公告编号：2022-21 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|---------------------------| | □ 是 √ 否 | 本报告期 | 上年同期 | 本报告期比上年同期增减 | ...

Financial Performance - The company reported a revenue increase of 15% year-over-year, reaching RMB 1.2 billion in 2021[14]. - The company's operating revenue for 2021 was RMB 6,560,077,586.40, representing a 9.23% increase compared to RMB 6,005,586,643.46 in 2020[16]. - The net profit attributable to shareholders of the listed company for 2021 was RMB 348,548,495.99, an increase of 7.29% from RMB 324,859,557.55 in 2020[16]. - The basic earnings per share for 2021 was RMB 0.56, up from RMB 0.52 in 2020, reflecting a 7.69% increase[16]. - The total revenue for 2021 reached ¥6,560,077,586.40, representing a 9.23% increase from ¥6,005,586,643.46 in 2020[155]. - The company achieved export revenue of USD 325,017 thousand in 2021, indicating exposure to foreign exchange risk[192]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[14]. - Future guidance indicates a projected revenue growth of 20% for 2022, aiming for RMB 1.44 billion[14]. - The company is actively pursuing market expansion strategies, as indicated by the involvement of independent directors with diverse industry backgrounds[40]. - The company plans to strengthen its market position amid challenges such as rising costs and intensified competition in the pharmaceutical sector[147]. - The company is focusing on talent acquisition, hiring 163 new employees, including 66 with master's degrees or higher[146]. Research and Development - The company has invested RMB 50 million in R&D for new drug development, focusing on oncology and chronic diseases[14]. - R&D expenses for the year totaled RMB 340 million, with 12 drug approvals and 14 patents granted[143]. - The company completed the construction of the injection drug R&D platform and GMP renovation project[144]. - The company is focused on enhancing its innovation capabilities through partnerships with research institutions and the establishment of a gene and cell engineering research center[150]. - R&D investment increased by 12.61% to RMB 328,029,328.76 from RMB 291,288,719.68 in 2020, representing 5.00% of operating revenue[175]. Corporate Governance - The company has established a strong governance framework with independent directors overseeing key operations, ensuring compliance and strategic direction[40]. - The company maintains a complete separation from its controlling shareholder in terms of business operations, assets, personnel, and financial management[71]. - The company has strengthened its corporate governance and compliance with relevant laws and regulations during the reporting period[73][74]. - The board of directors confirmed compliance with corporate governance codes during the fiscal year ending December 31, 2021[87]. - The company has appointed three independent non-executive directors, one of whom possesses financial management expertise[89]. Financial Health and Liabilities - The net cash flow from operating activities decreased by 38.33% to RMB 259,116,960.17 in 2021, down from RMB 420,186,808.35 in 2020[16]. - The company's total liabilities decreased by 0.56% to RMB 3,680,888,823.85 in 2021, compared to RMB 3,701,662,448.12 in 2020[16]. - The debt-to-asset ratio of the company is 50.20%[191]. - The company's liquidity ratios are stable, with a current ratio of 110.08% and a quick ratio of 69.00%[187]. - The company's total liabilities decreased by 44.17% in financing activities cash inflow to RMB 612,183,982.00 from RMB 1,096,573,800.00 in 2020[177]. Shareholder Information - The largest shareholder, China Hualu Holdings Group Co., Ltd., holds 32.65% of the shares, totaling 204,864,092 shares[26]. - The company has no pledged or frozen shares among its top shareholders[29]. - Shareholders holding more than 10% of voting shares can request a special general meeting, and if the board does not respond within 30 days, they may convene the meeting themselves[117]. - The company has established a contact point for shareholders to submit written inquiries or requests[119]. - The company has committed to covering reasonable expenses incurred by shareholders who convene a meeting due to the board's inaction[117]. Employee and Management Information - The company had a total of 6,533 employees as of December 31, 2021, with a total payroll of RMB 602.446 million for the year[58]. - The total annual remuneration for directors, supervisors, and senior management in 2021 amounted to RMB 13.4287 million[54]. - The company has established a training system that enhances employee capabilities and ensures effective management operations[61]. - The company's directors and senior management hold a total of 821,270 shares, with no holdings reported for supervisors[50]. - The company’s current board and senior management's term ends on December 22, 2023, indicating a stable leadership structure[48]. Audit and Compliance - The audit committee confirmed that the 2021 financial statements were prepared in accordance with the relevant accounting standards and accurately reflected the company's financial position[67][69]. - The audit committee recommended the reappointment of the auditing firm for the 2022 financial year[70]. - The independent directors attended all 11 board meetings and 4 audit committee meetings, with no absences reported[65][66]. - The company has established effective internal controls in all significant aspects, achieving its internal control objectives without any major deficiencies[81]. - The internal control audit report issued by the accounting firm confirmed that the company maintained effective financial reporting internal controls as of December 31, 2021[84].

证券代码：000756 证券简称：新华制药 公告编号：2021-57 山东新华制药股份有限公司 关于参加山东辖区上市公司 2021 年度投资者网上集体接待日的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 为增强与广大投资者的沟通互动，做好投资者关系管理工作，切实提高上市 公司透明度、规范运作和公司治理水平，山东新华制药股份有限公司（以下简称 "公司"）将参加由山东证监局、山东上市公司协会联合举办的"2021 年山东 辖区上市公司投资者网上集体接待日"活动，本次活动由深圳市全景网络有限公 司承办，现将有关事项公告如下： 本次集体接待日活动将通过深圳市全景网络有限公司提供的互联网平台举 行，投资者可以登录"全景·路演天下"网站（http://rs.p5w.net/）参与公司 本次投资者集体接待日活动，活动时间为 2021 年 11 月 16 日（周二）14:00 至 16:00。 届时公司董事会秘书曹长求先生将通过网络在线交流的形式，与投资者就公 司治理及社会责任/ESG、经营状况、发展战略、风险防控、投资者保护、三季度 报告等投资者关注的问题进行沟通。欢 ...

Financial Performance - The company's operating revenue for Q3 2021 was CNY 1,389,149,183.41, representing a 2.69% increase year-over-year[4] - Net profit attributable to shareholders for the same period was CNY 85,253,975.87, up 15.59% compared to the previous year[4] - The net profit after deducting non-recurring gains and losses was CNY 66,051,847.57, reflecting a 6.01% increase year-over-year[4] - Basic earnings per share for Q3 2021 was CNY 0.14, an increase of 16.67% year-over-year[4] - Total operating revenue for Q3 2021 reached CNY 4,940,192,936.36, an increase of 6.5% compared to CNY 4,638,516,349.70 in the same period last year[20] - Net profit for Q3 2021 was CNY 297,252,235.38, representing a 11.2% increase from CNY 267,382,674.75 in Q3 2020[22] - Earnings per share (EPS) for Q3 2021 was CNY 0.46, compared to CNY 0.40 in the same quarter last year[22] - The company reported a total comprehensive income of CNY 249,238,018.45 for Q3 2021, compared to CNY 230,590,612.90 in Q3 2020[22] Cash Flow and Liquidity - The net cash flow from operating activities for the first nine months was CNY 230,422,146.43, a decrease of 42.84% compared to the same period last year[7] - The net cash flow from operating activities for Q3 2021 was ¥230,422,146.43, a decrease of 42.7% compared to ¥403,088,862.25 in Q3 2020[23] - Total cash inflow from operating activities was ¥4,249,122,895.25, slightly down from ¥4,252,520,386.22 in the previous year[23] - Cash outflow for purchasing goods and services increased to ¥2,623,192,208.55 from ¥2,506,920,043.15, representing a rise of 4.6%[23] - The net cash flow from investing activities was -¥175,630,676.15, an improvement from -¥190,003,477.30 in Q3 2020[23] - Cash inflow from financing activities totaled ¥503,104,800.00, down from ¥919,500,000.00 in the same quarter last year[24] - The net cash flow from financing activities was -¥100,041,207.71, compared to a positive cash flow of ¥13,923,804.11 in Q3 2020[24] - The ending balance of cash and cash equivalents was ¥675,142,439.65, down from ¥798,135,230.21 at the end of Q3 2020[24] - The company received cash from investment income of ¥9,105,486.40, an increase from ¥8,589,271.94 in the previous year[23] - Cash paid to employees increased to ¥632,172,231.81 from ¥548,783,311.56, reflecting a rise of 15.2%[23] Assets and Liabilities - Total assets at the end of the reporting period amounted to CNY 7,189,407,562.48, a 1.36% increase from the end of the previous year[4] - The total assets of Shandong Xinhua Pharmaceutical Co., Ltd. reached approximately RMB 7.19 billion, an increase from RMB 7.09 billion in the previous period, reflecting a growth of about 1.4%[18] - The company's current assets totaled approximately RMB 2.69 billion, slightly up from RMB 2.69 billion in the previous period, indicating stable liquidity[18] - Accounts receivable increased significantly to approximately RMB 706.56 million, compared to RMB 379.91 million in the previous period, marking an increase of about 86%[17] - Inventory decreased to approximately RMB 901.66 million from RMB 1.12 billion, a decline of about 19.8%, suggesting improved inventory management[18] - Short-term borrowings rose to approximately RMB 330.36 million, up from RMB 200.42 million, indicating a 64.7% increase in leverage[18] - The total liabilities decreased to CNY 3,601,189,190.99 from CNY 3,701,662,448.12, a reduction of approximately 2.7%[20] - The total equity attributable to shareholders of the parent company increased to CNY 3,406,442,460.59 from CNY 3,223,793,819.25, marking an increase of 5.7%[20] Government Support and Strategic Initiatives - The company received government subsidies amounting to CNY 20,147,478.70 during the reporting period[6] - The company plans to expand its market presence through a non-public offering of A-shares, as approved in recent board meetings[14] - The company has adjusted the exercise price of its stock option plan from RMB 5.98 to RMB 5.76 per share, impacting the incentive structure for employees[13] - The stock option incentive plan has been revised, reducing the number of eligible participants from 185 to 184, with a total of 16.2 million options granted[13] Audit and Reporting - The company did not undergo an audit for the Q3 report[25]

Financial Performance - The company's operating revenue for the first half of 2021 was approximately CNY 3.55 billion, representing an increase of 8.07% compared to the same period last year[14]. - The total profit for the reporting period was approximately CNY 260.36 million, reflecting a year-on-year increase of 12.70%[14]. - The net profit attributable to shareholders of the listed company was approximately CNY 200.08 million, which is a 16.12% increase compared to the previous year[14]. - The net profit after deducting non-recurring gains and losses was approximately CNY 185.86 million, up by 20.47% year-on-year[14]. - The basic earnings per share for the reporting period was CNY 0.32, an increase of 14.29% compared to the same period last year[14]. - The total revenue for the reporting period reached RMB 3,551,043,752.95, representing an increase of 8.07% compared to RMB 3,285,772,716.57 in the same period last year[66]. - The total comprehensive income for the first half of 2021 was RMB 171,687,869.96, compared to RMB 140,225,562.96 in the previous year, reflecting an increase of 22.47%[141]. - The company's total equity as of June 30, 2021, was RMB 2,941,392,330.37, slightly up from RMB 2,900,622,666.04 at the end of 2020, showing a growth of 1.41%[139]. Assets and Liabilities - The total assets of the company at the end of the reporting period were approximately CNY 7.27 billion, an increase of 2.52% from the end of the previous year[14]. - The total liabilities at the end of the reporting period were approximately CNY 3.75 billion, reflecting a 1.23% increase compared to the previous year[14]. - The total liabilities reached RMB 3,747,286,649.76, slightly up from RMB 3,701,662,448.12, reflecting a marginal increase of 1.2%[135]. - The total current liabilities amounted to RMB 2,507,368,417.07, an increase from RMB 2,381,039,242.59 as of December 31, 2020, representing a growth of approximately 5.3%[135]. - The total non-current liabilities decreased to RMB 1,239,918,232.69 from RMB 1,320,623,205.53, indicating a reduction of about 6.1%[135]. Cash Flow - The net cash flow from operating activities was approximately CNY 165.10 million, a decrease of 17.70% compared to the same period last year[14]. - The cash and cash equivalents net increase decreased by 74.72%, highlighting a decline in cash inflow from financing activities[64]. - The net cash flow from operating activities for the current period is RMB 87,524,492.14, a decrease of 45.8% compared to RMB 161,203,550.66 in the previous period[148]. - Cash inflow from financing activities is RMB 485,704,800.00, down 46.0% from RMB 899,500,000.00 in the previous period[148]. Research and Development - The company increased R&D investment to RMB 164 million in the first half of the year, a year-on-year growth of 10.28%[40]. - Research and development expenses increased by 10.28% to RMB 163,835,401.81, indicating a focus on innovation[60]. - Research and development expenses for the first half of 2021 were RMB 170,257,317.76, compared to RMB 157,166,732.04 in the same period of 2020, representing an increase of 8.93%[141]. - The company obtained 6 drug approvals, including Erbesartan, and has 10 products awaiting review at CDE[40]. Market Performance - The export sales of key raw materials such as EPA and hormone products increased by 86% and 216.8% respectively, while the export volume of solid preparations to the UK and Europe grew by 26.05%[38]. - Domestic sales of raw materials reached RMB 461 million, marking a 17.44% increase year-over-year, with new veterinary drug product sales up by 50%[38]. - The company's formulation products generated sales revenue of RMB 824 million, a 12.36% increase, with ten strategic formulation varieties seeing a 32.5% rise in sales volume[39]. - The company achieved export revenue of $174.51 million in the first half of 2021, with exposure to currency fluctuation risks[78]. Environmental Compliance - The company adheres to national environmental policies and will increase investment in environmental protection facilities[89]. - The company has not faced administrative penalties for environmental issues during the reporting period[92]. - The company operates as a key pollutant discharge unit, with specific measures in place to monitor and control emissions[93]. - Wastewater discharge standards are being met, with no exceedances reported for chemical oxygen demand and ammonia nitrogen[93]. - The company has implemented safety and environmental training to reduce environmental risks and ensure compliance[89]. Corporate Governance - The company has established a governance framework and confirmed compliance with corporate governance codes as of June 30, 2021[128]. - The audit committee has reviewed the accounting principles and methods adopted by the group for the six months ending June 30, 2021, and has agreed with the financial statements presented[129]. - The financial statements are prepared based on the going concern assumption, with no significant doubts about the company's ability to continue operations[165]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[8]. - The board of directors recommended not to distribute dividends for the first half of 2021, maintaining a conservative financial strategy[85]. - As of June 30, 2021, the total number of shareholders was 32,152, including 46 H-share shareholders and 32,106 A-share shareholders[18]. - The top ten shareholders held a total of 204,864,092 shares, accounting for 32.65% of the total shares[19].

Financial Performance - The company's operating revenue for Q1 2021 was CNY 1,768,119,883.04, representing a 3.64% increase compared to CNY 1,705,982,914.01 in the same period last year[7] - The net profit attributable to shareholders for Q1 2021 was CNY 100,276,326.14, a 16.21% increase from CNY 86,286,544.27 year-on-year[7] - The net profit after deducting non-recurring gains and losses was CNY 96,454,109.91, up 22.80% from CNY 78,547,417.73 in the previous year[7] - The total operating income for Q1 2021 was CNY 949,499,126.18, a decrease of 4.02% from CNY 989,274,388.58 in the same period last year[45] - The net profit for Q1 2021 reached CNY 105,675,789.00, representing an increase of 13.00% compared to CNY 93,483,236.19 in Q1 2020[43] - The company achieved a net profit attributable to shareholders of CNY 100,276,326.14, up from CNY 86,286,544.27, marking a growth of 15.93%[43] - The total profit for Q1 2021 was CNY 129,187,925.43, an increase of 12.66% from CNY 114,647,500.02 in Q1 2020[1] Cash Flow - The company's cash flow from operating activities was CNY 89,368,875.29, down 14.83% from CNY 104,929,221.85 in the same period last year[7] - Net cash inflow from financing activities in Q1 2021 was RMB 28,806,822.77, a decrease of 95.15% compared to the same period last year, mainly due to a loan of RMB 600,000,000.00 obtained from the controlling shareholder in the previous year[16] - Operating cash inflow totaled CNY 1,328,906,874.60, a slight increase from CNY 1,318,507,689.52 in the previous period[49] - Net cash outflow from operating activities was CNY 1,239,537,999.31, compared to CNY 1,213,578,467.67 in the prior period[50] - Cash and cash equivalents at the end of the period amounted to CNY 788,049,366.09, a decrease from CNY 1,225,308,621.24 in the previous period[51] - Net cash flow from financing activities was CNY 28,806,822.77, significantly lower than CNY 593,389,904.31 in the same period last year[51] - Cash inflow from financing activities totaled CNY 414,967,280.00, down from CNY 620,000,000.00 in the previous year[50] - The net increase in cash and cash equivalents was CNY 65,486,139.53, compared to CNY 647,684,027.87 in the previous year[51] - The company reported a decrease in cash flow from operating activities net amounting to CNY 6,698,332.02, down from CNY 113,856,792.83 year-over-year[52] Assets and Liabilities - Total assets at the end of the reporting period were CNY 7,279,400,356.04, an increase of 2.63% from CNY 7,092,952,190.04 at the end of the previous year[7] - The net assets attributable to shareholders increased by 4.21% to CNY 3,359,487,089.39 from CNY 3,223,793,819.25 at the end of the previous year[7] - Total liabilities increased to CNY 3,744,102,094.08 in Q1 2021 from CNY 3,701,662,448.12 in Q4 2020, reflecting a rise of approximately 1.14%[36] - The total non-current liabilities increased to CNY 1,593,939,088.94 from CNY 1,320,623,205.53, indicating a rise of about 20.6%[36] - Short-term borrowings increased by 54.06% to CNY 308,774,051.97 compared to the beginning of the year, while long-term borrowings rose by 55.89% to CNY 721,352,672.51[15] Accounts Receivable and Inventory - Accounts receivable as of March 31, 2021, were CNY 707,881,350.32, up 86.33% compared to the beginning of the year, mainly due to expanded sales scale[15] - Accounts receivable increased significantly to CNY 514,069,169.07 from CNY 297,382,259.35, representing a growth of about 73%[37] - Inventory decreased to RMB 914,867,443.33 as of March 31, 2021, down from RMB 1,124,364,262.39 at the end of 2020[32] - Inventory decreased to CNY 486,041,915.73 from CNY 625,250,916.84, a reduction of approximately 22.3%[37] Investment and Other Income - Investment income for Q1 2021 was RMB 1,699,415.30, a significant increase from RMB -1,665,484.39 in the same period last year, primarily due to increased investment income from joint ventures[16] - Other income for Q1 2021 was CNY 5,812,444.68, a decrease of 44.88% from the previous year, primarily due to reduced government subsidies received[15] - The company reported an investment income of CNY 1,699,415.30, a significant recovery from a loss of CNY 1,665,484.39 in the previous year[45] Research and Development - Research and development expenses amounted to CNY 77,494,772.47, up from CNY 74,898,770.72, indicating a growth of 3.92% year-over-year[1] Earnings and Profitability - The basic earnings per share for Q1 2021 were CNY 0.16, compared to CNY 0.14 in the same quarter last year, reflecting a 14.29% increase[43] - The gross profit margin improved to 23.73% in Q1 2021, compared to 24.38% in Q1 2020[1] - The total operating costs for Q1 2021 were CNY 1,645,192,254.65, slightly higher than CNY 1,598,810,056.97 in Q1 2020[1] - Other comprehensive income after tax was CNY 790,288.84, a recovery from a loss of CNY 43,485,988.58 in the previous year[43]